Menlo Care
This article was originally published in The Gray Sheet
Executive Summary
Developing a version of an injectable paste made of its Aquavene hydrophilic polymer for the treatment of urinary stress incontinence, President and CEO David Maupin announces at the Hambrecht & Quist conference on Jan. 11. The firm believes the paste will not be absorbed by the body and therefore will not need to be reinjected. Maupin also said the privately-held firm "would like to crank up" its R&D efforts, adding that an initial public offering would be "an important thing for us"....